Sanofi India Ltd Reports -2% Net Sales YTD Growth and +6% Profit from Operations for Q2 2025

Sanofi India Limited (SIL) announced its financial results for the quarter ended June 30, 2025. The Company recorded a 9% decline in net sales on a comparable basis of continuing business. The domestic market saw the successful launch of Soliqua®, reinforcing their comprehensive diabetes portfolio. Toujeo® maintained strong performance with high single-digit growth. Export sales were affected by non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio. The Company achieved a 6% increase in operating profit for the year-to-date period ended June 2025, due to cost optimization and enhanced operational efficiencies. Sanofi remains committed to enhancing operational efficiency and broadening access to both established products and innovative therapies across India.